Liver disease and extracorporeal supportprimary
1 project
ALIVER focused on developing DIALIVE, a liver dialysis device for acute-on-chronic liver failure treatment.
Organization
UNIVERSITATSMEDIZIN ROSTOCK
German academic medical center specializing in liver disease therapy, neurological diagnostics, and analytical mass spectrometry within large European health consortia.
University medical centerhealthDENo active H2020 projects
H2020 projects
6
As coordinator
0
Total EC funding
€1.5M
Unique partners
87
What they do
Their core work
University Medicine Rostock is a German academic medical center combining clinical care with translational research, particularly in liver disease treatment and neurological diagnostics. Their H2020 portfolio centers on developing diagnostic and therapeutic tools — from blood biomarkers for early Alzheimer's detection to liver dialysis devices for acute liver failure. They also contribute analytical chemistry expertise in ion mobility and mass spectrometry techniques, and participate in digital health and ageing research.
Core expertise
What they specialise in
Analytical mass spectrometry techniquesprimary
1 project
IMPACT trained researchers in soft chemical ionization mass spectrometry, ion mobility spectrometry, and proton transfer reaction methods.
2 projects
BBDiag developed blood biomarker-based diagnostic tools for early-stage Alzheimer's; CoCA studied comorbid conditions of ADHD.
Digital health and patient adherencesecondary
1 project
HEARTEN developed a cooperative mHealth environment for managing heart failure patients.
Ageing and healthspan researchsecondary
1 project
Ageing with elegans used C. elegans models to validate factors affecting health and disease across the lifespan.
Evolution & trajectory
How they've shifted over time
Early focus
Analytical chemistry and ageing
Recent focus
Clinical diagnostics and liver therapy
Their early H2020 projects (2015-2016) show a split focus: digital health tools (HEARTEN), ageing biology (Ageing with elegans), and analytical chemistry instrumentation (IMPACT). By 2017, the portfolio shifted decisively toward clinical medicine — liver dialysis devices (ALIVER), Alzheimer's blood biomarkers (BBDiag), and neuropsychiatric comorbidities (CoCA). This trajectory suggests a move from broad research participation toward more targeted translational medical applications.
Moving toward translational clinical tools — diagnostic biomarkers and therapeutic devices — making them a strong partner for medtech and clinical validation projects.
Collaboration profile
How they like to work
Role: specialist_contributorReach: European22 countries collaborated
University Medicine Rostock operates exclusively as a consortium participant, never coordinating, which positions them as a reliable specialist contributor rather than a project driver. With 87 unique partners across 22 countries in just 6 projects, they integrate into large, diverse consortia — averaging roughly 15 partners per project. This pattern suggests they are valued for specific clinical or analytical expertise rather than project management capacity.
Despite a modest project count, they have built a wide network of 87 unique partners spanning 22 countries, indicating participation in large pan-European health consortia with broad geographic coverage.
Why partner with them
What sets them apart
University Medicine Rostock bridges analytical chemistry instrumentation with clinical medicine — an unusual combination that lets them contribute both laboratory technique development and clinical validation within the same institution. Their involvement in ALIVER (liver dialysis devices) positions them at the intersection of medical device development and hepatology, a niche where few academic medical centers in northern Germany operate. For consortium builders, they offer a dual capability: deep clinical access for patient studies and analytical measurement expertise.
Notable projects
Highlights from their portfolio
- ALIVERDeveloping DIALIVE, a dedicated liver dialysis device for acute-on-chronic liver failure — a clear path-to-market medical device project.
- BBDiagBlood-based biomarker diagnostics for early Alzheimer's detection — addresses one of the biggest unmet needs in neurology.
- IMPACTMarie Curie training network in ion mobility and chemical ionization mass spectrometry — built analytical chemistry capacity and trained next-generation researchers.
Cross-sector capabilities
Analytical instrumentation and mass spectrometryDigital health and mHealth applicationsBiomarker development for diagnosticsAgeing and age-related disease models
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →